Insulin glargine U100/lixisenatide and insulin degludec/liraglutide are fixed-ratio combinations containing basal insulin and a glucagon-like peptide-1 receptor agonist capable of reducing both fasting and postprandial blood glucose levels with a single formulation. This study aimed to compare the time in range (TIR) and the time below range (TBR) level 1 using professional continuous glucose monitoring and to establish criteria for the differential use of the fixed-ratio combinations.

中文翻译：

---

使用专业连续血糖监测比较德谷胰岛素/利拉鲁肽和甘精胰岛素 U-100/利西拉来对 2 型糖尿病患者的疗效和安全性

甘精胰岛素 U100/利西拉肽和德谷胰岛素/利拉鲁肽是固定比例的组合，含有基础胰岛素和胰高血糖素样肽 1 受体激动剂，能够通过单一配方降低空腹和餐后血糖水平。本研究旨在使用专业的连续血糖监测来比较范围内时间 (TIR) 和范围内时间 (TBR) 1 级，并建立固定比率组合的差异使用标准。